High accuracy variant calling with detailed reporting on mutations found in each sample. Chosen from a range of molecularly targeted FDA-approved, off label, or experimental therapies. Patients are matched with trials that are seeking specific molecular profiles. Reporting on Micro-satellite instability (MSI) and tumor mutational burden (TMB).